Fig. 2From: Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trialsForest plots of PFS (A) and OS (B) between combination therapy and monotherapy in all patient populationBack to article page